MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Company Registration Number:
08971622 (England and Wales)
Unaudited statutory accounts for the year ended 30 September 2021
Period of accounts
Start date: 1 October 2020
End date: 30 September 2021
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Contents of the Financial Statements
for the Period Ended 30 September 2021
Directors report | |
Profit and loss | |
Balance sheet | |
Additional notes | |
Balance sheet notes |
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 30 September 2021
Principal activities of the company
Additional information
The directors are responsible for preparing the Strategic report, the Directors' report and the financial statements in accordance with applicable law and regulations.Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law, including FRS 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs and profit or loss of the company for that period. In preparing these financial statements, the directors are required to:- select suitable accounting policies and then apply them consistently;- make judgments and accounting estimates that are reasonable and prudent;- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.Financial risk managementThe company has exposures to three main areas of risk - foreign exchange currency exposure, liquidity risk and interest rate risk. The company has very limited credit, price and cash flow risk as the company is primarily a holding company for the European trading entities of the Meridian Group.Foreign exchange transactional currency exposureThe Group is exposed to currency exchange rate risk due to a significant proportion of its receivables and payables being denominated in non-Sterling currencies. The net exposure of each currency is monitored but as the Meridian Group has an immaterial net risk no active management, by way of foreign exchange contracts, of this risk is undertaken locally. This is constantly reviewed and natural hedging opportunities are aggressively followed.Liquidity riskThe objective of the Meridian Group in managing liquidity risk is to ensure that it can meet its financial obligations as and when they fall due. The Meridian Group expects to meet its financial obligations through operating and investment income cash flows. The anticipated investment income of the company significantly exceeds its financial obligations. In addition the company’s primary obligations are to other companies within the Meridian Group. In the event that the operating cash flows would not cover all the financial obligations there is an ability to negotiate amended terms and in the context of the Meridian Group as a whole the liabilities are not material.Interest rate riskThe company borrows from other Meridian Group entities at arms length rates. It has no external bank debt and therefore while there is some interest rate risk it is minimal given current market conditions.EmployeesArrangements exist within the company for the provision and reporting of information of interest to employees. In addition to management and staff meetings, bulletins, leagues and newsletters are produced. Employees are paid bonuses and incentives based upon personal and company performance.Applications for employment by disabled persons are always fully considered, bearing in mind the respective aptitudes and abilities of the applicant concerned. In the event of members of staff becoming disabled every effort is made to ensure that their employment with the company continues. Disabled employees share the same opportunities for training and career development as any other member of staff.Post balance sheet eventsDividend payment to Meridian Bioscience, Inc of £38,500,000 as of 18th August 2022.Disclosure of information to auditorThe directors confirm that:- so far as the director is aware, there is no relevant audit information of which the company's auditor is unaware, and- the directors have taken all the steps that ought to have taken as directors in order to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information.AuditorErnst and Young were appointed on 22nd December 2020 as auditors. They will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.
Directors
The directors shown below have held office during the whole of the period from
1 October 2020 to 30 September 2021
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Profit And Loss Account
for the Period Ended
2021 | 2020 | |
---|---|---|
| £ | £ |
Turnover: | | |
Gross profit(or loss): | | |
Administrative expenses: | ( | ( |
Other operating income: | | |
Operating profit(or loss): | | |
Interest receivable and similar income: | | |
Interest payable and similar charges: | ( | ( |
Profit(or loss) before tax: | | |
Tax: | ( | ( |
Profit(or loss) for the financial year: | | |
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Balance sheet
As at
Notes | 2021 | 2020 | |
---|---|---|---|
| £ | £ | |
Fixed assets | |||
Tangible assets: | 3 | | |
Investments: | 4 | | |
Total fixed assets: | | | |
Current assets | |||
Debtors: | 5 | | |
Cash at bank and in hand: | | | |
Total current assets: | | | |
Creditors: amounts falling due within one year: | 6 | ( | ( |
Net current assets (liabilities): | | | |
Total assets less current liabilities: | | | |
Total net assets (liabilities): | | | |
Capital and reserves | |||
Called up share capital: | | | |
Share premium account: | | | |
Other reserves: | | | |
Profit and loss account: | | | |
Total Shareholders' funds: | | |
The notes form part of these financial statements
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Balance sheet statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Notes to the Financial Statements
for the Period Ended 30 September 2021
-
1. Accounting policies
Basis of measurement and preparation
These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102 Tangible fixed assets depreciation policy
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. The company adds to the carrying amount of an item of fixed assets the cost of replacing part of such an item when that cost is incurred, if the replacement part is expected to provide incremental future benefits to the company. The carrying amount of the replaced part is derecognised. Repairs and maintenance are charged to the Statement of comprehensive income during the period in which they are incurred. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method. The estimated useful lives range as follows: Computer equipment - 4 years The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Statement of comprehensive income. Valuation information and policy
2.6 Impairment of assetsAt each reporting date fixed assets are reviewed to determine whether there is any indication that those assets have suffered an impairment loss. If there is an indication of possible impairment, the recoverable amount of any affected asset is estimated and compared with its carrying amount. If estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount, and an impairment loss is recognised immediately in the Statement of comprehensive income.If an impairment loss subsequently reverses, the carry amount of the asset is increased to the revised estimate of its recoverable amount, but not in excess of the amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised immediately in the Statement of comprehensive income.2.7 Investments in subsidiariesInvestments comprise investments in unquoted equity instruments which are measured at cost less accumulated impairment. Other accounting policies
2.8 DebtorsShort term debtors are initially recognised at transaction proceeds and subsequently carried at amortised cost using the effective interest method. At the end of each reporting period assets are assessed for objective evidence of impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.2.9 Cash and cash equivalents Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value. 2.10 Creditors Short term trade creditors are initially recognised at the transaction price and subsequently measured at amortised cost using the effective interest method. 2.11 Taxation Current tax is recognised for the amount of corporation tax payable in respect of the taxable profit for the current or past reporting periods using the tax rates and laws that that have been enacted or substantively enacted by the reporting date. Deferred tax is recognised in respect of all timing differences at the reporting date, except as otherwise indicated. Deferred tax assets are only recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. If and when all conditions for retaining tax allowances for the cost of a fixed asset have been met, the deferred tax is reversed. Deferred tax is recognised when income or expenses from a subsidiary or associate have been recognised, and will be assessed for tax in a future period, except where: - the group is able to control the reversal of the timing difference; and - it is probable that the timing difference will not reverse in the foreseeable future. Deferred tax is calculated using the tax rates and laws that that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. Deferred tax assets and deferred tax liabilities are offset only if: - the company has a legally enforceable right to set off current tax assets against current tax liabilities, and - the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realise the assets and settle the liabilities simultaneously. 2.12 Foreign currency translation Functional currency and presentation currency The financial statements of the company are presented in the currency of the primary economic environment in which the company operates (its functional currency). The results and financial position are presented in Sterling (£). Transactions and balances In preparing the financial statements, transactions in currencies other than the functional currency (foreign currencies) are recognised at the spot rate at the dates of the transactions, or at an average rate where this rate approximates the actual rate at the date of the transaction. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences are recognised in profit or loss in the period in which they arise. 2.13 Dividends paid Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting. 2.14 Interest and finance costs Interest incurred in the course of carrying out the day to day running of the company's business is expensed to the Statement of comprehensive income in the period in which it arises. 2.15 Pensions Defined contribution pension plan The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations. The contributions are recognised as an expense in the Statement of comprehensive income when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the company in independently administered funds. Provisions are made where an event has taken place that gives the company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation. Provisions are charged as an expense to profit or loss in the year that the company becomes aware of the obligation, and are measured at the best estimate at the Statement of financial position date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties. When payments are eventually made, they are charged to the provision carried in the Statement of financial position.2.17 Exceptional items Exceptional items are transactions that fall within the ordinary activities of the company but are presented separately due to their size or incidence.
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Notes to the Financial Statements
for the Period Ended 30 September 2021
-
2. Employees
2021 2020 Average number of employees during the period 14 14
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Notes to the Financial Statements
for the Period Ended 30 September 2021
3. Tangible assets
Land & buildings | Plant & machinery | Fixtures & fittings | Office equipment | Motor vehicles | Total | |
---|---|---|---|---|---|---|
Cost | £ | £ | £ | £ | £ | £ |
At 1 October 2020 | | | ||||
Additions | ||||||
Disposals | ||||||
Revaluations | ||||||
Transfers | ||||||
At 30 September 2021 | | | ||||
Depreciation | ||||||
At 1 October 2020 | | | ||||
Charge for year | | | ||||
On disposals | ||||||
Other adjustments | ||||||
At 30 September 2021 | | | ||||
Net book value | ||||||
At 30 September 2021 | | | ||||
At 30 September 2020 | | |
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Notes to the Financial Statements
for the Period Ended 30 September 2021
4. Fixed assets investments note
The Company acquired Exalenz Bioscience Ltd. on 30th April 2020 at the value of £45,166,149 ($56,747,506).During the year, the Company made investment to its wholly-owned subsidiary, Meridian Bioscience Israel HoldingLtd., in the form of the Capital Note of £7,243,696 ($10,000,000). Capital Note issue dates:- $1,000,000 issued on 3rd June 2021- $2,000,000 issued on 21st June 2021- $7,000,000 issued on 20th September 2021An impairment charge was recognised in 2019 with relation to the investment held in Meridian Bioscience EuropeSrl as a result of the financial performance of this entity.
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Notes to the Financial Statements
for the Period Ended 30 September 2021
5. Debtors
2021 | 2020 | |
---|---|---|
£ | £ | |
Other debtors | | |
Total | | |
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Notes to the Financial Statements
for the Period Ended 30 September 2021
6. Creditors: amounts falling due within one year note
2021 | 2020 | |
---|---|---|
£ | £ | |
Trade creditors | | |
Taxation and social security | | |
Accruals and deferred income | | |
Other creditors | | |
Total | | |